icon-folder.gif   Conference Reports for NATAP  
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study: The NEED study
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
W.-W. Su1, C.-W. Hsu2, C.-M. Lee3, C.-Y. Peng4, W.-L. Chuang5, J.-H. Kao6, R.-N. Chien7, H.-C. Chu8, Y.-H. Huang9, Y.-F. Liaw2 1Changhua Christian Hospital, Changhua, Taiwan, 2Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, 3Chang Gung Memorial Hospital, Kaohsiung, 4China Medical University Hospital, Taichung, 5Kaohsiung Medical University Hospital, Kaohsiung, 6National Taiwan University Hospital, Taipei, 7Chang Gung Memorial Hospital, Keelung, 8Tri-Service General Hospital, 9Taipei Veterans General Hospital, Taipei, Taiwan
from Jules: yesterday I distributed to the NATAP listserve the EASL 2014 oral presentation of Pegasys+entecavir in HBV study presented by Brouwer et al, their study had different patient population than the Chinese NEED Study, perhaps different genotypes, and different study design. Here is the oral presentation of the other study. The study design appears different: 6 weeks only of the antiviral while patients in the other study received 48 weeks of entecavir in combination with 48 weeks entecavir, with nonresponders extending to 72 weeks. And then in this study the HIV-DNA response we were provided was after 4 weeks.